{
    "clinical_study": {
        "@rank": "55218", 
        "arm_group": {
            "arm_group_label": "HAPLO", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Rationale: Fludarabine, cyclophosphamide, anti-thymocyte globulin and low-dose total body\n      irradiation (LD-TBI) may induce the engraftment cross the immunologic barrier in the setting\n      of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion\n      of CD3 cells may contribute to prevent developing severe acute graft versus host disease\n      (GVHD) in haploidentical transplantation.\n\n      Purpose: Phase II trials to evaluate the efficacy of haploidentical stem cell\n      transplantation with fixed dose of T cells after in vitro T cell depletion using CD3\n      monoclonal antibody for children with acquired severe aplastic anemia"
        }, 
        "brief_title": "Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acquired Aplastic Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of life-threatening marrow failure (severe aplastic anemia) of nonmalignant\n             etiology meeting 2 of the following criteria:\n\n               -  Granulocyte count < 500/mm3,\n\n               -  Corrected reticulocyte count < 1%,\n\n               -  Platelet count < 20,000/mm3\n\n          -  No HLA-identical family member or closely matched (8 of 8 HLA-locus match) unrelated\n             marrow donor available\n\n          -  HLA-haploidentical related donor available\n\n        Exclusion Criteria:\n\n          -  Paroxysmal nocturnal hemoglobinuria or Fanconi anemia\n\n          -  Clonal cytogenetic abnormalities or myelodysplastic syndromes\n\n          -  Active fungal infections\n\n          -  HIV positive\n\n          -  Severe disease other than aplastic anemia that would severely limit the probability\n             of survival during the graft procedure\n\n          -  Pregnant or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01759732", 
            "org_study_id": "AMCPHO-SCT1202"
        }, 
        "intervention": [
            {
                "arm_group_label": "HAPLO", 
                "description": "40mg/M2 once daily IV on days -7 to -4", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "description": "60 mg/kg IV on day-3 and -2", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "intervention_name": "anti-thymocyte globulin", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological", 
                "other_name": "Beginning on day 4 and continuing until blood counts recover"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "description": "200 cGy per day on D-5 & -4", 
                "intervention_name": "Total body irradiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "HAPLO", 
                "description": "Immunogenetic depletion on CliniMACS", 
                "intervention_name": "CD3-depleted hematopoietic cell transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Antilymphocyte Serum", 
                "Cyclophosphamide", 
                "Fludarabine monophosphate", 
                "Lenograstim", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Aplastic anemia", 
            "T cell dose", 
            "CD3 depletion", 
            "Haploidentical hematopoietic stem cell transplantation"
        ], 
        "lastchanged_date": "December 30, 2012", 
        "link": [
            {
                "description": "Anemia", 
                "url": "http://www.nlm.nih.gov/medlineplus/anemia.html"
            }, 
            {
                "description": "Fludarabine", 
                "url": "http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&objectHandle=DBMaint&..."
            }
        ], 
        "location": {
            "contact": {
                "email": "hojim@amc.seoul.kr", 
                "last_name": "Ho Joon Im, MD, PhD", 
                "phone": "82-2-3010-3371"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Kyung Nam Koh, MD, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Haploidentical Stem Cell Transplantation With Fixed Dose of T Cells After in Vitro T Cell Depletion Using CD3 Monoclonal Antibody for Children With Acquired Severe Aplastic Anemia", 
        "overall_contact": {
            "email": "hojim@amc.seoul.kr", 
            "last_name": "Ho Joon Im, MD, PhD", 
            "phone": "82-2-3010-3371"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Ho Joon Im, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess engraftment rate and survival of haploidentical stem cell transplantation with fixed dose of T cells after in vitro T cell depletion using CD3 monoclonal antibody for children with acquired severe aplastic anemia", 
            "safety_issue": "Yes", 
            "time_frame": "2 years posttransplant"
        }, 
        "reference": [
            {
                "PMID": "22533862", 
                "citation": "Burroughs LM, Woolfrey AE, Storer BE, Deeg HJ, Flowers ME, Martin PJ, Carpenter PA, Doney K, Appelbaum FR, Sanders JE, Storb R. Success of allogeneic marrow transplantation for children with severe aplastic anaemia. Br J Haematol. 2012 Jul;158(1):120-8. doi: 10.1111/j.1365-2141.2012.09130.x. Epub 2012 Apr 26."
            }, 
            {
                "PMID": "22546497", 
                "citation": "Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul;18(7):1007-11. doi: 10.1016/j.bbmt.2012.04.014. Epub 2012 Apr 27."
            }, 
            {
                "PMID": "22635243", 
                "citation": "Xu LP, Liu KY, Liu DH, Han W, Chen H, Chen YH, Zhang XH, Wang Y, Wang FR, Wang JZ, Huang XJ. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Bone Marrow Transplant. 2012 Dec;47(12):1507-12. doi: 10.1038/bmt.2012.79. Epub 2012 May 28."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01759732"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Asan Medical Center", 
            "investigator_full_name": "Ho Joon Im", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "22055111", 
            "citation": "Koh KN, Im HJ, Kim BE, Choi ES, Jang S, Kwon SW, Park CJ, Seo JJ. Haploidentical haematopoietic stem cell transplantation using CD3 or CD3/CD19 depletion and conditioning with fludarabine, cyclophosphamide and antithymocyte globulin for acquired severe aplastic anaemia. Br J Haematol. 2011 Nov 5; [Epub ahead of print] No abstract available."
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients who failed to engraft by 28 days", 
                "measure": "To assess engraftment and graft failure", 
                "safety_issue": "Yes", 
                "time_frame": "28 days posttransplant"
            }, 
            {
                "description": "Number of patients with acute GVHD.", 
                "measure": "To estimate the risk of acute GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "100 days posttransplant"
            }, 
            {
                "description": "Number of death after transplantation", 
                "measure": "To assess treatment related mortality", 
                "safety_issue": "Yes", 
                "time_frame": "100 days posttransplant"
            }, 
            {
                "measure": "To estimate overall survival and failure free survival", 
                "safety_issue": "No", 
                "time_frame": "1 year posttransplant"
            }
        ], 
        "source": "Asan Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Asan Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}